Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study.

Aims: Assess the relationship between New York Heart Association (NYHA) functional class and cardiovascular (CV) outcomes in obstructive hypertrophic cardiomyopathy (HCM).

Materials And Methods: This retrospective cohort study used the Optum Market Clarity database with linked claims and electronic health records. Adults (aged ≥18 years) with obstructive HCM and ≥1 NYHA class assessment after first HCM diagnosis were eligible (selection period: 2007-2021).

Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records.

Importance: Other than single-center case studies, little is known about generalized pustular psoriasis (GPP) flares.

Objective: To assess GPP flares and their treatment, as well as differences between patients with and patients without flares documented in US electronic health records (EHRs).

Design, Setting, And Participants: This retrospective cohort study included adult patients with GPP (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code L40.

Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.

Background: Few validated instruments exist for use in hidradenitis suppurativa (HS) trials.

Objectives: To develop a novel HS Investigator Global Assessment (HS-IGA) and to validate its psychometric properties.

Methods: Development of HS-IGA involved discussion among stakeholders, including patients, within HISTORIC.

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

Importance: Demonstrating the value of therapies from a patient's perspective is increasingly important for patient-centered care.

Objective: To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of life (HRQL), and mental health among patients with moderate to severe psoriasis.

Design, Setting, And Participants: The UltIMMa-1 and UltIMMa-2 studies were replicate 52-week phase 3, randomized, multisite, double-blind, placebo-controlled and active comparator-controlled trials conducted in 139 sites (including hospitals, academic medical centers, clinical research units, and private practices) globally in Asia-Pacific, Japan, Europe, and North America.

Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis.

The primary objective of the study was to evaluate the measurement properties of the patient-reported four-item Psoriasis Symptom Scale (PSS).: Analysis of phase-III data on the efficacy of risankizumab to assess psychometric characteristics of the PSS in patients with moderate-to-severe psoriasis. PSS items had a good range of symptom severity coverage.

Physician management of moderate-to-severe acute pain: results from the Physicians Partnering Against Pain (P³) study.

Objective: To evaluate differences among physician specialties in the management of acute pain including prescribing practices and management of opioid-related side effects.

Design And Participants: The Physicians Partnering Against Pain (P³) survey was a nationwide study of US physicians and their patients with severe to moderate acute pain (<3 months).

Main Measures: Physicians were surveyed about volume of patients with moderate-to-severe acute pain in their practice, frequency of prescribing opioid analgesics, percentage of these patients returning for a follow-up visit after treatment, reasons patients discontinue treatment, frequency of recommending or prescribing treatment for opioid-related gastrointestinal (GI) side effects, and frequency of patients taking opioid analgesics that take additional treatments to manage GI side effects.

Consumer assessment of healthcare providers and systems surgical care survey: benefits and challenges.

Objective: To describe the feasibility and initial results of the implementation of a continuous quality improvement project using the newly available Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey (S-CAHPS), in a small cohort of otolaryngology-head and neck surgery practices.

Study Design: Prospective observational study using a newly validated health care consumer survey.

Setting: Two community-based and 2 university-based otolaryngology-head and neck surgery outpatient clinic practices.

Cost-effectiveness of antiplatelet therapy for secondary stroke prevention.

Antiplatelet therapy is recommended over anticoagulants for the secondary prevention of vascular death in patients with noncardioembolic ischemic stroke or transient ischemic attack based upon the 2006 American Heart Association/American Stroke Association guidelines for the prevention of stroke and the National Stroke Association guidelines for the management of transient ischemic attack. Aspirin is commonly used as a cornerstone antiplatelet agent considering its mild but definite prevention benefit and low costs. Other antiplatelet strategies that are currently recommended include extended-release dipyridamole plus low-dose aspirin (Aggrenox((R)), Asasantin((R))) and clopidogrel.

Evidence of Innovative Uses of Performance Measures Among Purchasers.

Purchasers are interested in quality of care and performance information for a number of reasons including helping purchasers to make value-based purchasing decisions, holding health plans and providers accountable, and monitoring the care received by enrollees. Interviews with purchasers were conducted in several geographic areas. Purchasers included in the study were large employers, business coalitions, and governments.